- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 223/18 - Dibenzazepines; Hydrogenated dibenzazepines
Patent holdings for IPC class C07D 223/18
Total number of patents in this class: 51
10-year publication summary
|
6
|
1
|
3
|
4
|
1
|
1
|
0
|
3
|
1
|
0
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7958 |
4 |
| Bristol-myers Squibb Company | 5080 |
3 |
| Samsung Display Co., Ltd. | 30585 |
2 |
| Sumitomo Chemical Company, Limited | 8808 |
2 |
| Kyoto University | 2732 |
2 |
| Nagase & Co., Ltd. | 223 |
2 |
| Rohm and Haas Electronic Materials Korea Ltd. | 546 |
2 |
| Vandria SA | 8 |
2 |
| Contineum Therapeutics, Inc. | 9 |
2 |
| Hoffmann-La Roche Inc. | 3060 |
1 |
| University of Southern California | 2016 |
1 |
| University of South Florida | 1817 |
1 |
| Aarhus Universitet | 370 |
1 |
| API Corporation | 211 |
1 |
| BIAL - Portela & CA, S.A. | 243 |
1 |
| Cnrs | 106 |
1 |
| Dana-Farber Cancer Institute, Inc. | 2455 |
1 |
| Domain Therapeutics | 47 |
1 |
| Guangzhou Kingmed Center for Clinical Laboratory | 11 |
1 |
| Hamari Chemicals, Ltd. | 33 |
1 |
| Other owners | 19 |